Roth Capital set a $14.00 price target on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) in a research note released on Wednesday. The brokerage currently has a buy rating on the stock.

Several other research firms have also recently issued reports on AVDL. Zacks Investment Research raised Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a sell rating to a hold rating in a report on Tuesday, November 14th. Ladenburg Thalmann Financial Services upped their price target on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from $27.00 to $30.00 in a report on Thursday, September 7th. BidaskClub raised shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a strong sell rating to a sell rating in a research note on Saturday, December 9th. Finally, Langenberg & Company reissued a buy rating and set a $30.00 target price (up from $27.00) on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in a research note on Thursday, September 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The company has an average rating of Hold and an average price target of $21.50.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) opened at $9.02 on Wednesday. The stock has a market capitalization of $354.34, a price-to-earnings ratio of 16.37 and a beta of 1.34. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a twelve month low of $7.52 and a twelve month high of $12.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.53 and a quick ratio of 1.47.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.13. The company had revenue of $39.68 million for the quarter, compared to analysts’ expectations of $38.22 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a return on equity of 33.92% and a net margin of 44.47%. The firm’s revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.08) earnings per share. equities research analysts forecast that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post 0.32 EPS for the current fiscal year.

In other Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share news, Director Craig R. Stapleton sold 254,265 shares of the business’s stock in a transaction on Monday, November 27th. The shares were sold at an average price of $9.35, for a total transaction of $2,377,377.75. Following the sale, the director now directly owns 253,413 shares of the company’s stock, valued at approximately $2,369,411.55. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael S. Anderson bought 5,000 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were purchased at an average cost of $8.86 per share, for a total transaction of $44,300.00. The disclosure for this purchase can be found here. 5.07% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp increased its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 1.7% in the second quarter. State Street Corp now owns 31,782 shares of the company’s stock worth $351,000 after acquiring an additional 523 shares during the last quarter. Stifel Financial Corp increased its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 4.3% in the second quarter. Stifel Financial Corp now owns 60,500 shares of the company’s stock worth $667,000 after acquiring an additional 2,500 shares during the last quarter. Sei Investments Co. increased its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 29.5% in the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock worth $140,000 after acquiring an additional 2,900 shares during the last quarter. Trexquant Investment LP increased its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 18.7% in the third quarter. Trexquant Investment LP now owns 36,218 shares of the company’s stock worth $380,000 after acquiring an additional 5,718 shares during the last quarter. Finally, State of Tennessee Treasury Department increased its stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 32.7% in the third quarter. State of Tennessee Treasury Department now owns 23,291 shares of the company’s stock worth $245,000 after acquiring an additional 5,736 shares during the last quarter. 67.75% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/roth-capital-analysts-give-avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-a-14-00-price-target/1797215.html.

About Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with Analyst Ratings Network's FREE daily email newsletter.